Clover Health Investments, Corp.
CLOV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.45 | 0.06 | 0.03 | -0.01 |
| FCF Yield | 2.16% | -25.37% | -47.08% | -16.16% |
| EV / EBITDA | -30.02 | -1.64 | -1.37 | -2.60 |
| Quality | ||||
| ROIC | -12.46% | -65.98% | -77.52% | -109.59% |
| Gross Margin | 26.61% | 20.30% | 9.44% | -5.38% |
| Cash Conversion Ratio | -0.81 | 0.54 | 0.60 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.73% | -5.04% | 17.68% | 47.12% |
| Free Cash Flow Growth | 128.59% | 44.12% | 26.38% | -9,593.07% |
| Safety | ||||
| Net Debt / EBITDA | 4.33 | 0.57 | 0.39 | 0.48 |
| Interest Coverage | 0.00 | -29,332.71 | -210.32 | -37.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -9.75 | -10.08 |
| Cash Conversion Cycle | 12.17 | 19.45 | -0.39 | -15.71 |